quzyttir
Quzyttir (Cetirizine Hydrochloride) is a histamine-1 receptor antagonist used to treat Perennial Allergic Rhinitis, Urticaria.
Cetirizine Hydrochloride · by Esteve
Available as a generic: Children's Cetirizine Hydrochloride Allergy
Key facts
- Active ingredient
- Cetirizine Hydrochloride
- Drug class
- Histamine-1 Receptor Antagonist
- Form
- Injectable
- Strength
- Cetirizine Hydrochloride 10MG/ML (10MG/ML)
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- perennial allergic rhinitis, urticaria
- Manufacturer
- Esteve
- Half-life
- about 8.3 hours (mean in healthy adults) (how long it stays in your system)
- What the pharmacy pays
- ~$0.06 per ml — not your price
- FDA application
- NDA211415
What is Quzyttir?
From the FDA label:Cetirizine hydrochloride, the active component of QUZYTTIR, is a selective histamine-1 (H 1 ) receptor antagonist. The chemical name is (±) –[2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperzinyl] ethoxy]acetic acid, dihydrochloride. Cetirizine hydrochloride is a racemic compound with an empirical formula of C 21 H 25 ClN 2 O 3 •2HCl. The molecular weight is 461.82 and the chemical structure is shown below: Cetirizine hydrochloride is a white, crystalline powder and is water soluble. QUZYTTIR is a sterile, clear, colorless, non-pyrogenic, isotonic solution for intravenous injection. Each mL of QUZYTTIR injection contains 10 mg cetirizine hydrochloride (equivalent to cetirizine 8.42 mg) and 6.5 mg sodium chloride, USP to adjust solution tonicity, in water for injection, USP. QUZYTTIR is supplied in 2 mL size amber glass vials for single use. Each 2 mL size amber glass vial contains 1 mL drug solution with 10 mg cetirizine hydrochloride (10 mg/mL). QUZYTTIR's pH is maintained between 4.5 to 6.5 with sodium hydroxide and/or hydrochloric acid as needed. The osmolality of QUZYTTIR injection is between 255 to 340 mOsmol. Chemical Structure
How to use
QUZYTTIR is a single use injectable product for intravenous administration only. The recommended dosage regimen is once every 24 hours as needed for treatment of acute urticaria. Administer QUZYTTIR as an intravenous push over a period of 1 to 2 minutes. QUZYTTIR is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function [see Pediatric Use ( 8.4 )]. If using as an antihistamine prior to infusion product administration, refer to infusion product prescribing information for instructions. For intravenous administration only ( 2 ) Recommended dosages: Adults and adolescents ≥ 12 years of age and older: 10 mg ( 2.1 ) Children 6 to 11 years: 5 mg or 10 mg ( 2.2 ) Children 6 months to 5 years: 2.5 mg ( 2.3 ) Recommended dosage regimen is once every 24 hours as needed for acute urticaria ( 2 ) 2.1 Adults and adolescents 12 years of age and older The recommended dosage is 10 mg administered by intravenous injection. 2.2 Children 6 to 11 years of age The recommended dosage is 5 mg or 10 mg depending on symptom severity administered by intravenous injection. 2.3 Children 6 months to 5 years of age The recommended dosage is 2.5 mg administered by intravenous injection.
Side effects
The following clinically significant adverse reaction is described elsewhere in the labeling: Somnolence/Sedation [see Warnings and Precautions ( 5.1 )] The most common adverse reactions (incidence less than 1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis. Most common adverse reactions (incidence equal to or greater than 2%) with use of oral cetirizine hydrochloride are somnolence, fatigue, dry mouth, pharyngitis, and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, call TerSera Therapeutics LLC at 1-844-334-4035 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Oral cetirizine hydrochloride The following adverse reactions associated with the use of oral cetirizine hydrochloride were identified in clinical trials. In clinical trials in patients 12 years and older the most common adverse reactions to oral cetirizine hydrochloride occurring with a 2% or greater incidence and greater than placebo were somnolence (14%), fatigue (6%), dry mouth (5%), pharyngitis (2%), and dizziness (2%). In clinical trials in children 6 to…
Warnings
Important safety information
Somnolence/Sedation: Exercise caution when driving a car or operating potentially dangerous machinery ( 5.1 ) 5.1 Somnolence/Sedation In clinical trials with QUZYTTIR and cetirizine hydrochloride tablets, the occurrence of somnolence/sedation has been reported in some patients. Exercise due caution when driving a car or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.
Who should not take Quzyttir
The use of QUZYTTIR is contraindicated in patients with a known hypersensitivity to cetirizine hydrochloride or any of its ingredients, levocetirizine, or hydroxyzine. Known hypersensitivity to cetirizine hydrochloride or any of its ingredients, levocetirizine, or hydroxyzine ( 4 )
Overdose — what happens if you take too much
Cases of adult and pediatric patients with overdoses of only oral cetirizine hydrochloride have been reported, some of which resulted in adverse reactions. Adult overdose cases involved patients 18 to 81 years of age receiving oral cetirizine hydrochloride doses of 70 mg to 800 mg (7 to 80 times the maximum recommended dosage of 10 mg/day in adults). The most commonly reported adverse reactions were somnolence and fatigue. Other reported adverse reactions included tachycardia, abdominal pain, nausea, and vomiting. Pediatric overdose cases involved patients 18 months to 15 years of age receiving oral cetirizine hydrochloride doses of 90 mg to 300 mg (9 to 72 times the maximum age recommended dose). The adverse reactions reported included: somnolence, difficulty walking, agitation/irritability, hard to swallow/articulate clearly, tachycardia, vomiting, mydriasis, and elevated creatinine phosphokinase. If overdose with QUZYTTIR occurs, treatment should be symptomatic or supportive, taking into account any concomitantly ingested medications. There is no known specific antidote to cetirizine hydrochloride. Cetirizine hydrochloride is not effectively removed by dialysis, and dialysis will be ineffective unless a dialyzable agent has been concomitantly ingested.
U.S. Poison Control: call or text 1-800-222-1222 (free, 24/7). In an emergency call 911. From the FDA label; not medical advice.
Interactions
No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect [see Clinical Pharmacology ( 12.3 )].
How long does Cetirizine Hydrochloride stay in your body?
The elimination half-life of cetirizine hydrochloride is about 8.3 hours (mean in healthy adults) — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. This is the parent drug's elimination half-life; cetirizine's only metabolite has negligible antihistaminic activity, so it does not prolong the effect. The half-life is shorter in young children (per the label, roughly 33-41% shorter in ages 2-5 and about 63% shorter in ages 6-23 months) and is expected to be longer in older adults and in people with kidney or liver impairment.
This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: CETIRIZINE HYDROCHLORIDE syrup (DailyMed).
Drug class
How this class works, per Antihistamines - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Quzyttir ranks — best-rated histamine-1 receptor antagonist for:
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Quzyttir treat?
- Quzyttir (Cetirizine Hydrochloride) may be used to treat perennial allergic rhinitis, urticaria, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Quzyttir work?
- Quzyttir is a histamine-1 receptor antagonist. H1 antihistamines work by blocking histamine, the chemical released during an allergic reaction, from attaching to H1 receptors. This prevents the sneezing, itching, runny nose, watery eyes, and hives that histamine would otherwise trigger.
- How much does Quzyttir cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $0.06 per ml, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Quzyttir?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Quzyttir. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Quzyttir?
- Quzyttir is marketed by Esteve. You can see Esteve's full profile, rating, and other products on pharmaranks.
- Is Quzyttir a brand-name or generic drug?
- Quzyttir is a brand-name product with the active ingredient Cetirizine Hydrochloride. Lower-cost generic equivalents containing Cetirizine Hydrochloride are available — ask your pharmacist.
- Is Quzyttir available over the counter?
- No. Quzyttir is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Quzyttir come in?
- Quzyttir is currently marketed as injectable, per the FDA's National Drug Code Directory.
- What class of drug is Quzyttir?
- Quzyttir is classified as histamine-1 receptor antagonist, per the FDA's Established Pharmacologic Class.
- Is Quzyttir FDA-registered?
- Quzyttir is on record with the U.S. FDA under application number NDA211415. You can verify this on its official FDA label.
- Is Quzyttir safe?
- There's no single safe-or-not verdict, and we don't yet have a composite recall-safety score for Quzyttir. Review its FDA-label side effects and warnings below, and always consult a licensed professional.
- What are the side effects of Quzyttir?
- Quzyttir's side effects are taken directly from its FDA label. From the label: The following clinically significant adverse reaction is described elsewhere in the labeling: Somnolence/Sedation [see Warnings and Precautions ( 5.1 )] The most common adverse reactions (incidence less than 1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot,… Both common and serious reactions are documented in full on this page. This is general reference from the FDA, not medical advice — always consult a professional.
Clinical content sourced from the FDA label via openFDA (U.S. FDA). View the FDA label on DailyMed → Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
Reviews
No reviews yet. Be the first to write one.
People also viewed
children's cetirizine hydrochloride allergy
Cetirizine Hydrochloride
children's cetirizine hydrochloride hives relief
Cetirizine Hydrochloride
children's zyrtec allergy
Cetirizine Hydrochloride
children's zyrtec hives
Cetirizine Hydrochloride
children's zyrtec hives relief
Cetirizine Hydrochloride
zerviate
Cetirizine Hydrochloride
Compare Quzyttir head-to-head
More histamine-1 receptor antagonist drugs
Guides for this medication
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
quzyttir
New